Navigation Links
Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
Date:3/19/2013

not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for MST-188, including in sickle cell disease, acute limb ischemia, and other indications, and plans for protecting its intellectual property related to MST-188, as well as the timing of activities related to those plans.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the potential for delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing clinical trial material, completing manufacturing process development activities, and being subject to a "clinical hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of MST-188 in any particular indication in which the Company determines to develop MST-188, including acute limb ischemia, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of MST-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA determines they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication are s
'/>"/>
SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Achieves ISO 13485 Certification
2. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
3. Echo Therapeutics Appoints Robert Doman to Board of Directors
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
7. PTC Therapeutics Closes $60 Million Private Financing
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
10. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... Reportlinker.com announces that a new market research report ... Patient Scales Industry http://www.reportlinker.com/p01374301/Global-Patient-Scales-Industry.html ... markets for Patient Scales in US$ Thousand by ... Baby Scales, Chair Scales, and Under Bed Scales. ... US, Canada, Japan, Europe, Asia-Pacific, Latin America, and ...
(Date:8/20/2014)... 2014 Phase I Trial of ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with ... that it has begun a Phase I, First in ... for the treatment of DME. The study,s Principal Investigator ... Institute, Joslin Diabetes Center; Harvard Medical School Department of ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Medical ® today announced that it has closed on ... by Singapore-based Crescent Point Group, with existing investors, Maverick ... Ventures and Affinity Capital, making additional investments. Sami Sindi, ... board of directors. Moelis & Company acted as financial ...
... Jan. 9, 2012  MolecularHealth, a clinico-molecular informatics company, ... two next generation product lines that translate patient-specific ... scientific evidence into safer, more effective drug choices ... producing genomic information falling drastically and clinical data ...
Cached Medicine Technology:Uptake Medical Announces Successful Completion of Series C Financing 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3
(Date:8/20/2014)... no secret that millions of Americans are struggling with ... Abuse, nearly 24 million Americans are using some form ... fact that the total number of users has increased ... struggle with substance abuse often feel there may never ... has released updated lists of substance abuse resources ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... -- Taking the widely used antibiotic clarithromycin ... causes, a new study suggests. Because millions of ... urgent confirmation, said the Danish researchers behind the study. ... and that guidelines for the use of the drug ... One heart expert wasn,t surprised by the finding, ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 If ... has found a cure for it. With extensive research on ... provider named ‘MetroMD’ claims to have perfected the art of ... you a brand new younger look with their revolutionary anti-aging ... secrets of the 21st century fountain of youth, the MD ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2
... may indicate underlying disease, study finds , , FRIDAY, Aug. 8 ... play a pivotal role in increasing an older American,s risk ... a new report says. , Levels of adiponectin increase in ... the cardiovascular health of older people, according to the new ...
... Alaska The University of Alaska Fairbanks campus will be ... 12-14, 2008. , The biennial conference is organized in ... Arctic Region and brings together international participants to address ... host to the 2008 conference. , More than150 guests ...
... Delivers Cheer, Medication and Equipment to Young Patients and Helps ... Raise Money for Make-A-Wish ... general,availability of its train-themed "JR" autonomous mobile robot to children,s,hospitals ... the,national Make-A-Wish Foundation for each JR TUG that is deployed. ...
... 1-inch cut behind uterus and into woman,s body cavity ... they say may be the first operation of its ... Hospital/Columbia University Medical Center removed a woman,s gallbladder without ... as part of an ongoing clinical research trial, involved ...
... EDT, Thursday, ... August 14, PRINCETON, ... advanced wound care products,announced plans to release its second quarter 2008 results ... the Company will,hold a conference call that same day to discuss the ...
... Inc. (NYSE: HGR ) is pleased to ... Hanger Orthopedic Group, Inc. to "positive",from "stable." Moody,s ... "We are pleased with the outlook change ... the last ten quarters," remarked George McHenry,Hanger,s Chief ...
Cached Medicine News:Health News:Fat Cell Protein Boosts Heart Attack Risk in Elderly 2Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:Derma Sciences Conference Call Advisory 2
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: